Metavia, Dong-A ST Affiliate, Expands Global Patents for MASH Treatment Compound
"48 Global Patents Registered and Filed"
Metavia, an affiliate of Dong-A ST, announced on March 13 that it has expanded the global patent portfolio for 'Vanoglifel (DA-1241)', a treatment currently under development for metabolic dysfunction-associated steatohepatitis (MASH).
Metavia stated, “A total of 48 patents have been registered and filed in countries including the United States, Europe, Japan, and China. Through this, Vanoglifel is expected to be protected by patents at least until 2035, and there is also the possibility that the patent period may be further extended in the future.”
Vanoglifel is a first-in-class oral synthetic drug based on the GPR119 mechanism of action, currently being developed for indications including MASH and type 2 diabetes.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, Metavia is also expanding the patent portfolio for DA-1726, which is under development as an obesity treatment. A total of 39 patents have been registered or filed for DA-1726 in the United States and other major countries worldwide. The company plans to establish a global intellectual property foundation for DA-1726 through 2041.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.